Overview

A Phase 2 Evaluation of Tonabersat for DME

Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
Phase:
Phase 2
Details
Lead Sponsor:
Jaeb Center for Health Research
Collaborators:
Juvenile Diabetes Research Foundation
National Eye Institute (NEI)
National Institutes of Health (NIH)